Abstract
Objective
To identify the potential biomarkers of interstitial cystitis/painful bladder syndrome
(IC), a chronic syndrome of bladder-centric pain with unknown etiology that has an
adverse impact on quality of life, we analyzed the urine and serum metabolomes of
a cohort of IC patients and non-disease controls (NC).
Methods
Home collection of serum and urine samples was obtained from 19 IC and 20 NC females
in the Veterans Affairs (VA) Health Care System. IC was diagnosed independently by
thorough review of medical records using established criteria. Biostatistics and bioinformatics
analyses, including univariate analysis, unsupervised clustering, random forest analysis,
and metabolite set enrichment analysis (MSEA), were then utilized to identify potential
IC biomarkers.
Results
Metabolomics profiling revealed distinct expression patterns between NC and IC. Random
forest analysis of urine samples suggested discriminators specific to IC; these include
phenylalanine, purine, 5-oxoproline, and 5-hydroxyindoleacetic acid. When these urinary
metabolomics-based analytes were combined into a single model, the AUC was 0.92, suggesting
strong potential clinical value as a diagnostic signature. Serum-based metabolomics
did not provide potential IC discriminators.
Conclusion
Analysis of serum and urine revealed that women with IC have distinct metabolomes,
highlighting key metabolic pathways that may provide insight into the pathophysiology
of IC. The findings from this pilot study suggest that integrated analyses of urinary
metabolites, purine, phenylalanine, 5-oxoproline, and 5-HIAA, can lead to promising
IC biomarkers for pathophysiology of IC. Validation of these results using a larger
dataset is currently underway.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to UrologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.Am J Obstet Gynecol. 2002; 187: 116-126
- Diagnosis of interstitial cystitis.J Urol. 1990; 143: 278-281
- International Consultation on IC - Rome, September 2004/Forging an International Consensus: progress in painful bladder syndrome/interstitial cystitis. Report and abstracts.Int Urogynecol J Pelvic Floor Dysfunct. 2005; : S2-S34
- Psychophysical evidence of hypersensitivity in subjects with interstitial cystitis.J Urol. 2005; 173: 1983-1987
- Interstitial cystitis.Curr Opin Urol. 2002; 12: 69-74
- Primary evaluation of patients suspected of having interstitial cystitis (IC).Eur Uro. 2004; 45: 662-669
- AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome.J Urol. 2011; 185: 2162-2170
- Interstitial cystitis: an unsolved enigma.Clin J Am Soc Nephrol. 2009; 4: 1844-1857
- Prevalence of painful bladder syndrome/interstitial cystitis-like symptoms in women: a population-based study in Korea.World J Urol. 2011; 29: 103-108
- Prevalence and correlates for interstitial cystitis symptoms in women participating in a health screening project.Eur Uro. 2007; 51 (discussion 809): 803-808
- Etiology, pathophysiology and biomarkers of interstitial cystitis/painful bladder syndrome.Arch Gynecol Obstet. 2017; 295: 1341-1359
- Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States.J Urol. 2011; 186: 540-544
- The misdiagnosis of interstitial cystitis/bladder pain syndrome in a VA population.Neurourol Urodyn. 2019; 38: 1966-1972
- Stratification of patients with interstitial cystitis/bladder pain syndrome according to the anatomical bladder capacity.Urolo. 2019; 123: 87-92
- Guideline of guidelines: bladder pain syndrome.BJU Int. 2018; 122: 729-743
- Purinergic signalling in the urinary bladder.Auton Neurosci. 2015; 191: 78-81
- Pathophysiology of interstitial cystitis.Int J Urol. 2019; : 12-15
- Omics' approaches to understanding interstitial cystitis/painful bladder syndrome/bladder pain syndrome.Int Neurourol J. 2012; 16: 159-168
- Role of NLRP3 inflammasome in the development of bladder pain syndrome interstitial cystitis.Ther Adv Urol. 2019; 11 (1756287218818030)
- Mechanisms underlying overactive bladder and interstitial cystitis/painful bladder syndrome.Front Neurosci. 2018; 12: 931
- Mechanisms of pain from urinary tract infection.Int J Urol. 2014; : 26-32
- Bladder afferent hyperexcitability in bladder pain syndrome/interstitial cystitis.Int J Urol. 2014; : 18-25
- The need for multi-omics biomarker signatures in precision medicine.Int J Mol Sci. 2019; : 20
- Regulation of human adipose tissue activation, gallbladder size, and bile acid metabolism by a beta3-adrenergic receptor agonist.Diabetes. 2018; 67: 2113-2125
- Integrated metabolomics assessment of human dried blood spots and urine strips.Metabolites. 2017; 7
- Microbiota-driven transcriptional changes in prefrontal cortex override genetic differences in social behavior.Elife. 2016; 5
- Metabolomics analysis of metabolic effects of nicotinamide phosphoribosyltransferase (NAMPT) inhibition on human cancer cells.PLoS One. 2014; 9e114019
- Possible application of Raman microspectroscopy to verify the interstitial cystitis diagnosis after potassium sensitivity test: phenylalanine or tryptophan as a biomarker.Dis Markers. 2007; 23: 147-152
- Purinergic P2 × 7 receptors as therapeutic targets in interstitial cystitis/bladder pain syndrome; key role of ATP signaling in inflammation.Bladder. 2019; 6: e38
- Up-regulation of P2 × 3 receptor during stretch of bladder urothelial cells from patients with interstitial cystitis.J Urol. 2004; 171: 448-452
Article info
Publication history
Published online: May 16, 2021
Accepted:
May 5,
2021
Received:
February 5,
2021
Footnotes
Conflicts of Interests: Some of authors declare conflict of interest. B.G., N.N., V.B., V.T., and M.K. are employees of BERG Health. The other authors have nothing to disclose.
CDC Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Identification
Copyright
© 2021 Published by Elsevier Inc.
